Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome

Blood

Volumn 122, Issue 4, 2013, Pages 567-570

  Mohamedali, Azim M ^a   Alkhatabi, Heba ^a   Kulasekararaj, Austin ^a   Shinde, Sneha ^a   Mian, Syed ^a   Malik, Farooq ^a   Smith, Alexander E ^a   Gäken, Joop ^a   Mufti, Ghulam J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; CCBL PROTEIN; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; GENOMIC DNA; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; NRAS PROTEIN; PROTEIN; PROTEIN P53; SF3B1 PROTEIN; SRSF2 PROTEIN; TET2 PROTEIN; U2AF35 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC MARKER; HUMAN; KARYOTYPE; KARYOTYPING; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; PILOT STUDY; PRIORITY JOURNAL; SANGER SEQUENCING; SINGLE NUCLEOTIDE POLYMORPHISM; UNIPARENTAL DISOMY; AGED; BLOOD EXAMINATION; BONE MARROW; BONE MARROW EXAMINATION; EVALUATION; GENETICS; METHODOLOGY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PREDICTIVE VALUE; UTILIZATION REVIEW;

AGED; BONE MARROW; BONE MARROW EXAMINATION; CYTOGENETIC ANALYSIS; DNA MUTATIONAL ANALYSIS; HEMATOLOGIC TESTS; HUMANS; KARYOTYPE; KARYOTYPING; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS;

EID: 84886299367     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-471847     Document Type: Article

References (19)

1. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-2506.
2. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376-3382.
3. Tiu RV, Gondek LP, O’Keefe CL, et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 2011;117(17):4552-4560.
4. Mohamedali A, Gäken J, Twine NA, et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood. 2007;110(9):3365-3373.
5. Bennett JM. Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary? Haematologica. 2013;98(4):490-491.
6. Tong WG, Quintás-Cardama A, Kadia T, et al. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer. 2012;118(18):4462-4470.
7. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol. 2009; 27(5):754-762.
8. Gondek LP, Tiu R, O’Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111(3):1534-1542.
9. Makishima H, Rataul M, Gondek LP, et al. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res. 2010;34(4):447-453.
10. Coleman JF, Theil KS, Tubbs RR, Cook JR. Diagnostic yield of bone marrow and peripheral blood FISH panel testing in clinically suspected myelodysplastic syndromes and/or acute myeloid leukemia: a prospective analysis of 433 cases. Am J Clin Pathol. 2011;135(6):915-920.
11. Braulke F, Schanz J, Jung K, et al. FISH analysis of circulating CD341 cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. Leuk Res. 2010;34(10):1296-1301.
12. Ishizawa M, Kobayashi Y, Miyamura T, Matsuura S. Simple procedure of DNA isolation from human serum. Nucleic Acids Res. 1991;19(20):5792.
13. Lea NC, Abdallah A, Kizilors A, et al. Kings Health Partners 17 Gene Amplicon Panel for Next Generation Sequencing One Stop Mutational Assessment In Myeloid Malignancies. ASH Annual Meeting Abstracts. 2011;118(21):748-.
14. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010;116(19):3923-3932.
15. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-829.
16. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12): 1090-1098.
17. Jerez A, Sugimoto Y, Makishima H, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 2012;119(25):6109-6117.
18. Jerez A, Gondek LP, Jankowska AM, et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol. 2012;30(12):1343-1349.
19. Jasek M, Gondek LP, Bejanyan N, et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia. 2010;24(1):216-219.